Charles Schwab
SION

Charles Schwab’s Sionna Therapeutics SION Stock Holding History

Charles Schwab’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.82M Sell
120,253
-3,433
-3% -$131K ﹤0.01% 2418
2025
Q4 		$5.09M Buy
123,686
+12,190
+11% +$462K ﹤0.01% 2448
2025
Q3 		$3.28M Buy
111,496
+18,664
+20% +$406K ﹤0.01% 2604
2025
Q2 		$1.61M Buy
92,832
+28,188
+44% +$369K ﹤0.01% 2738
2025
Q1 		$676K Buy
+64,644
New +$1.06M ﹤0.01% 2975

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Charles Schwab's SION Position: Q1 2026 in Review

Charles Schwab reduced its Sionna Therapeutics (SION) stake by 2.8% in Q1 2026, selling an estimated $131K and leaving 120,253 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2418.

Charles Schwab first reported a position in SION in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.09M in Q4 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Charles Schwab held 120,253 shares of Sionna Therapeutics worth $4.82M as of Q1 2026.
  • Charles Schwab sold 3,433 Sionna Therapeutics shares in Q1 2026, an estimated $131K.
  • Sionna Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #2418 holding.
  • Charles Schwab first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Charles Schwab's Sionna Therapeutics position peaked at $5.09M in Q4 2025.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.